Payment overview · 2025
General Payments
$4,602.49
137 reported records · 30 companies
Healthcare provider profile · identity verified
Mark D Bej, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · SHEFFIELD VILLAGE, OH · NPI 1427040914
Verified facts
What the public records show
CMS Open Payments records show Mark D Bej, MD received $4,602.49 in general payments during 2025 across 137 reported records.
JAZZ PHARMACEUTICALS INC. accounted for 12.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Epidiolex, Nayzilam, Nurtec Odt, Qulipta, Xcopri.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Qulipta by this doctor in 2024.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EPIDIOLEX as an associated drug or biological on 10990 records involving 3626 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Epidiolex by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Xcopri by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Briviact by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nayzilam as an associated drug or biological on 9542 records involving 3826 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nayzilam by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $580.77 | 12.6% | 9 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $462.01 | 10.0% | 12 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$336.47 | 7.3% | 19 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $334.17 | 7.3% | 9 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $305.21 | 6.6% | 6 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $269.90 | 5.9% | 8 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $246.17 | 5.3% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $233.64 | 5.1% | 10 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $228.49 | 5.0% | 2 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$187.54 | 4.1% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $176.71 | 3.8% | 8 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $155.60 | 3.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $128.88 | 2.8% | 7 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $124.90 | 2.7% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $118.68 | 2.6% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $97.73 | 2.1% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $97.16 | 2.1% | 5 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $80.69 | 1.8% | 4 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $61.80 | 1.3% | 4 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $54.20 | 1.2% | 2 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $47.47 | 1.0% | 3 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.35 | 1.0% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.28 | 0.9% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $40.81 | 0.9% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $36.98 | 0.8% | 2 | 2025 |
| Ceribell, Inc. | Unresolved — no canonical attribution shown | $27.59 | 0.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.40 | 0.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.14 | 0.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.72 | 0.5% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $14.03 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,452.49 | 136 |
| Consulting Fee | $150.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $562.07 | 8 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $372.39 | 8 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $326.86 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $306.45 | 8 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $305.21 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $299.46 | 7 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $269.90 | 8 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $233.64 | 10 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $187.54 | 6 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $155.60 | 2 | 2025 |
Source payment records
|
|||||
| XYREM Normalized: xyrem |
Drug | JAZZ PHARMACEUTICALS INC. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $143.43 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $128.88 | 7 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $124.90 | 1 | 2025 |
Source payment records
|
|||||
| XCOPRI Normalized: xcopri |
Drug | SK Life Science, Inc. | $117.90 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $97.73 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $97.16 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $74.06 | 4 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $61.80 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $55.42 | 3 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $47.73 | 2 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $45.35 | 2 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $43.28 | 2 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $41.89 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $40.81 | 2 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $36.98 | 2 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $32.10 | 1 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $31.76 | 2 | 2025 |
Source payment records
|
|||||
| POCKET EEG DEVICE Normalized: pocket eeg device |
Device | Ceribell, Inc. | $27.59 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 172 | exact normalized | Medicare Part D |
| EPIDIOLEX epidiolex |
2025 | Epidiolex | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Nayzilam nayzilam |
2025 | Nayzilam | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 55 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 74 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XCOPRI xcopri |
2025 | Xcopri | 2024 | 62 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
74 | suppressed by CMS |
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | EPIDIOLEX open payments reported associated product |
CMS Open Payments — General Payments 10990 supporting records · 3626 recipient NPIs · example record 1234297758 |
Epidiolex · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
55 | 11 |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
172 | 16 |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Nayzilam open payments reported associated product |
CMS Open Payments — General Payments 9542 supporting records · 3826 recipient NPIs · example record 1224348539 |
Nayzilam · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Topiramate | Topiramate | 546 | 89 |
| Gabapentin | Gabapentin | 522 | 101 |
| Memantine Hcl | Memantine Hcl | 364 | 80 |
| Duloxetine Hcl | Duloxetine Hcl | 250 | 49 |
| Tizanidine Hcl | Tizanidine Hcl | 232 | 60 |
| Donepezil Hcl | Donepezil Hcl | 222 | 56 |
| Clonazepam | Clonazepam | 216 | 31 |
| Zonisamide | Zonisamide | 173 | 30 |
| Briviact | Brivaracetam | 172 | 16 |
| Carbamazepine Er | Carbamazepine | 164 | 39 |
| Lacosamide | Lacosamide | 162 | 15 |
| Lamotrigine | Lamotrigine | 137 | 18 |
| Levetiracetam | Levetiracetam | 131 | 26 |
| Primidone | Primidone | 128 | 30 |
| Divalproex Sodium Er | Divalproex Sodium | 127 | 15 |
| Modafinil | Modafinil | 127 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 125 | 26 |
| Baclofen | Baclofen | 123 | 32 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 102 | 22 |
| Pregabalin | Pregabalin | 91 | 20 |
| Trazodone Hcl | Trazodone Hcl | 87 | 12 |
| Rivastigmine | Rivastigmine | 82 | 16 |
| Nortriptyline Hcl | Nortriptyline Hcl | 81 | 22 |
| Oxcarbazepine | Oxcarbazepine | 81 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 78 | 26 |
| Lamotrigine Er | Lamotrigine | 77 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 75 | 14 |
| Qulipta | Atogepant | 74 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 70 | suppressed |
| Alprazolam | Alprazolam | 69 | 15 |
| Buspirone Hcl | Buspirone Hcl | 64 | 13 |
| Xcopri | Cenobamate | 62 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 60 | 11 |
| Epidiolex | Cannabidiol (Cbd) | 59 | suppressed |
| Clobazam | Clobazam | 57 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 57 | 16 |
| Nurtec Odt | Rimegepant Sulfate | 55 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | 12 |
| Ethosuximide | Ethosuximide | 46 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 42 | 13 |
| Methocarbamol | Methocarbamol | 41 | 13 |
| Entacapone | Entacapone | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 33 | suppressed |
| Phenobarbital | Phenobarbital | 33 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 30 | suppressed |
| Levetiracetam Er | Levetiracetam | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Carbatrol | Carbamazepine | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 26 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 26 | suppressed |
| Topamax | Topiramate | 25 | suppressed |
| Felbamate | Felbamate | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 23 |
| Fycompa | Perampanel | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Valproic Acid | Valproic Acid | 20 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 19 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 18 | suppressed |
| Lamictal Xr | Lamotrigine | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Risperidone Odt | Risperidone | 17 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Nadolol | Nadolol | 16 | suppressed |
| Prednisone | Prednisone | 16 | 13 |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 15 | suppressed |
| Exelon | Rivastigmine | 15 | suppressed |
| Nayzilam | Midazolam | 15 | suppressed |
| Phenytoin | Phenytoin | 15 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 14 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 14 | suppressed |
| Copaxone | Glatiramer Acetate | 13 | suppressed |
| Keppra | Levetiracetam | 13 | suppressed |
| Rufinamide | Rufinamide | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Skyclarys | Omaveloxolone | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Dilantin-125 | Phenytoin | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Topiramate Er | Topiramate | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,602.49 · 137 records | JAZZ PHARMACEUTICALS INC. | ACTHAR, AMYVID, AUSTEDO XR, Briviact, CREXONT, EPIDIOLEX, Fintepla, GOMEKLI, Gamunex-C, KESIMPTA, KEVEYIS, KISUNLA, LUMRYZ, Leqembi, Motpoly XR, NURTEC ODT, Nayzilam, Ocrevus, Ocrevus Zunovo, POCKET EEG DEVICE, QULIPTA, REXULTI, Sunosi, TRUDHESA, UBRELVY, ULTOMIRIS, VALTOCO, VYEPTI, WAKIX, XCOPRI, XYREM, XYWAV, ZAVZPRET, ZEPOSIA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error